The Global Antimicrobial Susceptibility Testing Market, by Product Type (Manual Antimicrobial Susceptibility Testing Products (Susceptibility Testing Disks, Mic Strips and Susceptibility Plates), Automated Laboratory Instruments and Consumables), by Application (Antibacterial, Antifungal, Anti-parasitic, and Antiviral), by Method (Disk Diffusion, Rapid Automated AST, Broth Dilution, Gradient Diffusion, and Genotypic Methods) by Distribution Channel (Hospitals, Pathology/Diagnostic Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, and Contract Research Organizations) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 3,525.75 million in 2022 and expected to exhibit a CAGR of 6.4% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

The emergence of new resistance mechanisms and a decrease in the efficiency of treating common infectious diseases have resulted in the failure of microbial responses to standard treatment, leading to prolonged illness, higher health care expenditures, and an immense risk of death. The development of multidrug resistance (MDR) is a natural phenomenon; however, the inappropriate use of antimicrobial drugs, inadequate sanitary conditions, inappropriate food-handling, and poor infection prevention and control practices contribute to the emergence of multidrug resistance and encourage the further spread of MDR.

The increasing number of multidrug resistance cases in tuberculosis (TB), malaria, HIV, influenza, and others among the global population is expected to result in the increasing adoption of antimicrobial susceptibility testing to reduce resistance exposure during the forecast period.

For instance, according to the data provided by the World Health Organization (WHO) in November 2021, an estimated 3.4% of new tuberculosis (TB) cases and 18% of previously treated cases had multi-drug resistant TB or rifampicin-resistant TB (MDR-TB/ RR-TB) globally, in the year 2018.

Global Antimicrobial Susceptibility Testing Market – COVID-19 Impact (Economic Impact)

The coronavirus or COVID-19 outbreak started from Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. Economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat spread of coronavirus since 2020.

According to a data published by the Organization for Economic Co-operation and Development (OECD) in November 2020, COVID-19 has posed major challenges to the healthcare infrastructure in the Middle East & North Africa region. Some countries such as Lebanon, Morocco, and Tunisia, have been severely impacted with regards to the overall management of the COVID-19 crisis. Moreover, OECD states that countries such as Iran, Syria, Iraq, the Palestinian Authority, Yemen, and Libya faced lack of hospital beds and low COVID-19 testing capacities.

According to an article published by the Elsevier Public Health Emergency Collection journal in November 2020, it is estimated that during the COVID-19 pandemic, hospitals and healthcare systems in America (North America and Latin America) lost revenue of around US$ 202.6 billion, which is generated from providing healthcare services.

As a result of the pandemic, access to customers to sell and implement automated antimicrobial susceptibility testing (AST) systems decreased during March 2020 and throughout the second quarter of 2020, as hospitals became primarily focused on the COVID-19 pandemic. Due to limited access to current and potential customers, market players' ability to complete sales of new AST systems and implement previously sold systems has been significantly reduced, resulting in a decrease in the growth of consumable test kits.

Browse 45 Market Data Tables and 44 Figures spread through 258 Pages and in-depth TOC on “Antimicrobial Susceptibility Testing Market”- Global Forecast to 2022, by Product Type (Manual Antimicrobial Susceptibility Testing Products (Susceptibility Testing Disks, Mic Strips and Susceptibility Plates), Automated Laboratory Instruments and Consumables), by Application (Antibacterial, Antifungal, Anti-parasitic, and Antiviral), by Method (Disk Diffusion, Rapid Automated AST, Broth Dilution, Gradient Diffusion, and Genotypic Methods) by Distribution Channel (Hospitals, Pathology/Diagnostic Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, and Contract Research Organizations) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Antimicrobial Susceptibility Testing Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/antimicrobial-susceptibility-testing-market-2449

Factors such as increasing launches of product by key players to expand their presence are expected to drive the global antimicrobial susceptibility testing market growth.

For instance, in 2021, Thermo Fisher Scientific Inc., the world leader in serving science, and Q-linea, an innovative infection diagnostics company, announced the launch of automated ASTar System, a rapid antimicrobial susceptibility testing (rAST) system that provides true minimum inhibitory concentration (MIC) results in ≈ 6 hours.

Key Takeaways of the Global Antimicrobial Susceptibility Testing Market:

  • The global antimicrobial susceptibility testing market is expected to exhibit a CAGR of 6.4% over the forecast period, owing to increasing prevalence of sepsis. For instance, according to the Centers for Disease Control and Prevention (CDC), more than 1.7 Mn people in the U.S. suffer from sepsis annually and around 270,000 Americans die each year due to sepsis.
  • By product type, the consumables segment is expected to account for the largest market share in 2021, owing to increasing launches of product For instance, Bio-Rad Laboratories, Inc. is a leading maker of products for clinical diagnostics, laboratory research, and medical testing, offers the highest quality Mueller-Hinton Agar media for antimicrobial susceptibility testing. Bio-Rad Mueller-Hinton-F agar medium (Mueller-Hinton + 5% horse blood + ß-NAD, ß-Nicotinamide Adenine Dinucleotide) is used for antimicrobial susceptibility testing of streptococcus spp., and haemophilus spp.
  • Key players operating in the global antimicrobial susceptibility testing market include Thermo Fisher Scientific Inc. and BIOMÉRIEUX, HiMedia Laboratories, Alifax S.r.l. Italy, Creative Diagnostics, Resistell AG, Danaher, Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc., Bruker, Nissui Pharmaceutical Co., Ltd., Hoffmann-La Roche Ltd.,Synbiosis, Mast Group Ltd., ELITechGroup, Flinn Scientific, CONDALAB, Accelerate Diagnostics, Inc., and Zhuhai DL Biotech Co., Ltd.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo